Here's Why Ozempic And Mounjaro Rivals Won't Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime SoonForbes • 03/27/24
Eli Lilly (LLY) Advances While Market Declines: Some Information for InvestorsZacks Investment Research • 03/26/24
Here's how much people are willing to spend on weight loss drugs, according to a new surveyCNBC • 03/23/24
Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.Investors Business Daily • 03/21/24
Amazon's 1-2 Punch: AI-Powered Listings and Eli Lilly Deal Make AMZN a Must-BuyInvestorPlace • 03/21/24
Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?The Motley Fool • 03/20/24
After Soaring 130% Over the Past Year, Is Now a Good Time to Take Profits in Eli Lilly?The Motley Fool • 03/20/24
A new study cites the health risks of intermittent fasting. Could it lift Ozempic sales?Market Watch • 03/19/24
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?The Motley Fool • 03/19/24
The $1 Trillion Question: Will LLY, TSMC or TSLA Be Wall Street's Next Nvidia?InvestorPlace • 03/17/24